Posted in | Nanomedicine

Celator to Present at 2014 BIO International Convention and 9th Annual JMP Healthcare Conference

Published on June 18, 2014 at 4:15 AM

Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that the company's management team will present at the following conferences in June:

  • Derek Miller, Chief Business Officer, will present an overview of the company at the BIO Business Forum, part of the 2014 BIO International Convention, on Tuesday, June 24, 2014, at 10:30 a.m. PDT (1:30 pm EDT) , at the San Diego Convention Center in San Diego, CA.
  • Fred Powell, Chief Financial Officer, will present an overview of the company at the 9th Annual JMP Healthcare Conference, on Wednesday, June 25, 2014, at 2:00 p.m. EDT, at the Westin New York Grand Central Hotel in New York, NY. A live webcast will be available on the investor section of Celator's website at www.celatorpharma.com. An archived replay of the webcast will be available on the company's website for 30 days after the conference.

About Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes two clinical stage products, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia and CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; and preclinical stage product candidates, including CPX-571 (a liposomal formulation of irinotecan:cisplatin), and the hydrophobic docetaxel prodrug nanoparticle (HDPN) formulation being studied by the National Cancer Institute's Nanotechnology Characterization Laboratory. For more information, please visit the company's website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.

Source: http://www.celatorpharma.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit